Join Senseonics for a virtual KOL event featuring David T. Ahn, MD (Hoag Medical Group) and Jeff Ciaramita, MD (Mercy), who will join company management to discuss the next-generation Eversense^® 365 Continuous Glucose Monitoring (CGM) system, which was recently cleared by the U.S. Food and Drug Administration (FDA) for people with Type 1 and Type 2 diabetes aged 18 years and older.

The event will highlight Eversense 365 in clinical practice and include an overview of Senseonics’ commercial collaboration with the St. Louis-based healthcare system Mercy. Eversense 365, the world’s first one-year CGM system, represents a significant breakthrough in diabetes technology and management that is highly differentiated from short-term CGMs.

A live question and answer session will follow the formal presentations.